These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14916470)

  • 1. Studies of plasma quinidine content. III. The value of delayed absorptive coated tablets in oral quinidine therapy.
    SAMPSON JJ; FOREMAN H; SOLOMON BC
    Circulation; 1952 Apr; 5(4):534-8. PubMed ID: 14916470
    [No Abstract]   [Full Text] [Related]  

  • 2. Quinidine dosage, with special reference to an oral loading dose schedule.
    Collste P; Nordlander R
    Br J Clin Pharmacol; 1979 Mar; 7(3):293-7. PubMed ID: 427006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
    Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J
    Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum quinidine levels after administration of three different quinidine preparations.
    Henning R; Nyberg G
    Eur J Clin Pharmacol; 1973 Dec; 6(4):239-44. PubMed ID: 4591150
    [No Abstract]   [Full Text] [Related]  

  • 6. [Relative bioavailability of various quinidine preparations in man after a single oral dose].
    Terhaag B; Gieszinger U
    Pharmazie; 1982 Dec; 37(12):848-50. PubMed ID: 7163373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
    Regårdh CG; Johnsson G; Lundborg P; Perrson BA
    Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal absorption of quinidine from some solutions and commercial tablets.
    Guentert TW; Upton RA; Holford NH; Bostrom A; Riegelman S
    J Pharmacokinet Biopharm; 1980 Jun; 8(3):243-55. PubMed ID: 7420269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration.
    Greenblatt DJ; Pfeifer HJ; Ochs HR; Franke K; MacLaughlin DS; Smith TW; Koch-Weser J
    J Pharmacol Exp Ther; 1977 Aug; 202(2):365-78. PubMed ID: 577934
    [No Abstract]   [Full Text] [Related]  

  • 10. Disposition kinetics of two oral forms of quinidine.
    Mahon WA; Mayersohn M; Inaba T
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):566-75. PubMed ID: 1277713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gastric retention and enteric-coated tablets].
    Eikeland O
    Tidsskr Nor Laegeforen; 1978 Feb; 98(6):306-7. PubMed ID: 635860
    [No Abstract]   [Full Text] [Related]  

  • 12. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of oral quinidine in cardioversion of persistent atrial fibrillation.
    Kirpizidis C; Stavrati A; Geleris P; Boudoulas H
    J Cardiol; 2001 Dec; 38(6):351-4. PubMed ID: 11806093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophagitis caused by oral medication.
    Teplick JG; Teplick SK; Ominsky SH; Haskin ME
    Radiology; 1980 Jan; 134(1):23-5. PubMed ID: 7350610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
    Kharasch ED; Hoffer C; Whittington D
    Br J Clin Pharmacol; 2004 May; 57(5):600-10. PubMed ID: 15089813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative bioavailability of a standard and a sustained-release quinidine tablet.
    Gibson DL; Smith GH; Koup JR; Stewart DK
    Clin Pharm; 1982; 1(4):366-8. PubMed ID: 7185532
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetic analysis of intravenously and orally administered quinidine in cows.
    McGuirk SM; Muir WW; Sams RA
    Am J Vet Res; 1981 Sep; 42(9):1482-7. PubMed ID: 7325456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinidine concentration in serum. The stability during maintained treatment with two different types of delayed absorption tablets.
    Ditlefsen EM; Bjerkelund C
    Acta Med Scand; 1966 Nov; 180(5):537-42. PubMed ID: 5923373
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic analysis of intravenously and orally administered quinidine in horses.
    McGuirk SM; Muir WW; Sams RA
    Am J Vet Res; 1981 Jun; 42(6):938-42. PubMed ID: 7283244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Average steady-state plasma levels with slow release quinidine preparations].
    Normand JP; Roux A; Bardet J; Kahn JC; Maspoli JJ; Jarreau FX; Sansarricq M; Flouvat B; Bourdarias JP
    Arch Mal Coeur Vaiss; 1979 Sep; 72(9):1006-13. PubMed ID: 116611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.